Disarm Therapeutics Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
Disarm Therapeutics is a biotechnology company that is creating a new class of therapeutics to prevent axonal degeneration, a common yet unaddressed pathology that causes disability and disease progression in a broad range of neurological diseases. Disarm is developing therapeutics that inhibit the SARM1 protein, recently identified by our scientific founders as the central driver of axonal degeneration. Disarm’s breakthrough therapeutics are designed to prevent the loss of axons in chronic and acute diseases of the central, ocular, and peripheral nervous systems, including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. Disarm was co-founded by Atlas Venture, Drs. Jeffrey Milbrandt and Aaron DiAntonio of Washington University in St. Louis, and a team of exceptional scientists and drug developers committed to developing a new treatment paradigm for patients with neurological diseases. For more information, please visit www.disarmtx.com.